UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
about
PharmGKB summary: very important pharmacogene information for UGT1A1Pediatric Statin Administration: Navigating a Frontier with Limited DataSimvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 ProteinA systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.Mapping genes that predict treatment outcome in admixed populationsEffect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancerCarboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone HydrolysisThe emerging role of electronic medical records in pharmacogenomics.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsA pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.A simple model predicts UGT-mediated metabolism.Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.Role of pharmacogenetics on deferasirox AUC and efficacy.Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting.Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.Genetic variation in statin intolerance and a possible protective role for UGT1A1.Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indicesSolute Carrier (SLC) Family Transporters
P2860
Q24562836-8443682C-9649-4B47-9085-3699BA9AECC1Q28068014-7C6F7D7A-903A-48FE-8795-BB189FCC6235Q28550067-197B9794-06FA-4771-9D0A-8A0C629B9503Q33891588-03E3B5D9-E56F-4F32-B842-6FB29523F5ECQ34348337-C66C30DB-A319-4568-AFE1-4C715F31AB72Q34570918-F0EDF849-6355-4D14-A0E1-81216AD153F6Q34921957-FEE04AF9-449E-457D-A82E-0ADB8EC35CCBQ35138221-25DBD89D-939A-474A-9E85-511A225CE9B3Q35478918-67740C67-6299-49AC-9208-61737F67F2A1Q35915932-A9FE112D-95D6-4D31-A4E3-6B047AAC8B91Q35917726-9BCBE890-80D8-42CE-BA18-BA33029D1F55Q36050960-4FD78EB7-877F-45A7-8F27-B2AEBB950590Q36925256-0B75C7F5-65F7-428B-8585-DC99E38EC671Q37979858-4B7753D6-655B-49CC-A6F4-9F02E1C74508Q37997047-826AF648-95BB-4DC4-92F8-29D31D0DAF57Q38049379-B48AF381-63B5-4C97-A875-C99DC49AE2F0Q38707798-21FE09CE-6B11-4599-B700-DA9FBF073C17Q38780996-C81CF019-AEE8-482A-9DE4-8D7DBCC38D45Q38874222-C299DDB1-AE68-4961-B478-2FE57D7E51C8Q39474573-1F5EBEB0-247A-4D7A-B7FD-C7DABB19D8A1Q39669361-0E26BD37-EA08-47A3-BDD0-59CB08B71AC0Q39721147-A7214EDC-70D3-47FA-8F40-36B912D269DCQ39865051-CBEEF742-4C43-4794-B29F-6C0116B2A849Q42714050-FBD19E24-70E4-423C-8ACC-60B1F32F0798Q46397769-6E987715-C2E9-40FD-8266-B0E20863B8FCQ49903283-4A9CB988-6653-4A50-82A4-F90EBC94A2D3Q50054110-ECD872A8-2E5B-427E-B48D-5A007FBE5406Q57148214-FA502AC9-262E-482B-9DBD-B242CEEBA395Q57500258-D5DB2B33-A832-4B17-A302-2B8F7A137A63Q57684555-CCA0B02E-12B2-48D7-B8B7-43D1A1B7563E
P2860
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
UDP-glucuronosyltransferase (U ...... nization in vitro and in vivo.
@en
type
label
UDP-glucuronosyltransferase (U ...... nization in vitro and in vivo.
@en
prefLabel
UDP-glucuronosyltransferase (U ...... nization in vitro and in vivo.
@en
P2093
P2860
P50
P356
P1476
UDP-glucuronosyltransferase (U ...... nization in vitro and in vivo.
@en
P2093
J E Keskitalo
S Riedmaier
U M Zanger
P2860
P356
10.1038/CLPT.2009.181
P407
P577
2009-09-30T00:00:00Z